SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Russell Mid-Cap Value ETF (IWS) Be on Your Investing Radar?

Patience Pays: ETFs You Can Buy and Hold for the Long Run

Middle East tensions may keep markets volatile in the near term. Discover ETFs to buy and hold for long-term growth.

Is it Time to Pay Attention to Value ETF Investing Again?

As geopolitical risks rise and volatility lingers, value investing stands out as an attractive strategy. Look at ETFs to simplify the implementation of the strategy.

The Zacks Analyst Blog Highlights VTV, JAVA, AVLV, IWS and VBR

Amid market volatility, value ETFs like VTV, JAVA, AVLV, IWS, and VBR offer stability, undervalued stock exposure, and potential long-term gains for investors.

Why Value ETFs Investing Could Be a Smart Move Right Now

Amid market uncertainty and overvalued equities, value investing with ETFs offer a safer, long-term path to steady returns.

Should Invesco S&P MidCap Value with Momentum ETF (XMVM) Be on Your Investing Radar?

iShares Trust - iShares Russell Mid-Cap Value ETF

TempusAI Stock Surges On AI-Enabled Healthcare App Launch, Pelosi Buy: Retail Mood Stays Buoyant

Equity

Neutral Sentiment

TempusAI, Inc. (TEM) stock jumped on Tuesday after the company launched an artificial intelligence (AI)-enabled healthcare concierge app for patients, sending the retail community into a tizzy.The Chicago, Illinois-based company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care.TempusAI announced the nationwide launch of “olivia,” an AI-enabled healthcare concierge app that empowers patients by bringing their healthcare-related data into one central location. It will also leverage advanced AI to provide actionable insights.Olivia includes features such as smart profile summary, AI-enabled notetaker, medical image sharing, health monitoring and direct data import. The app is now available for both iOS and Android devices.Eric Lefkofsky, CEO of Tempus, said, “Now, as AI becomes increasingly integrated into healthcare, tools like olivia will be essential in helping patients understand and navigate their care.”“This app goes beyond organizing information; it’s a proactive partner empowering patients to steer their health with confidence and clarity.”Separately, Rep. Nancy Pelosi (D-Calif) recently added TempusAI to her portfolio of holdings. The “Periodic Transaction Report”&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2025/20026590.pdf">filed</a> by the former House Speaker on behalf of her and her husband Paul Pelosi showed that she bought&nbsp;50 call options to buy&nbsp;<a href="https://stocktwits.com/symbol/TEM">TempusAI stock</a> worth $50,001-$100,000. The call options have a strike price of $20 and an expiration date of Jan. 16, 2026.<figure class="image"><img style="aspect-ratio:631/143;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/temp_sentiment_ac8f9637df.png" alt="temp-sentiment.png" width="631" height="143"><figcaption>TEMP sentiment and message volume January 21, 2025, as of 11:35 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward TempusAI stock stayed ‘bullish’ (73/100). Retail chatter on the stock grew louder following these developments, with message volume at ‘extremely high’ levels.The stock was among the top five trending tickers on the platform.A watcher on the platform linked the move to Pelosi’s buy, with some suggesting a run up to $70.<stembedurl>https://stocktwits.com/EveryTimeICash/message/600850925</stembedurl>Another watcher commented that the duo of catalysts have squeezed the shorts out. According to Yahoo Finance data, about 5.54% of the outstanding shares were shorted as of Dec. 31.<stembedurl>https://stocktwits.com/Boring_Kitty/message/600850996</stembedurl>By mid-session, the stock jumped over 39% to $48.97, marking the highest level since early December.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: Nancy Pelosi Reveals Big Tech Trades With Apple, Nvidia, Amazon, Alphabet: How Does Retail Sentiment Stack Up?

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

TempusAI’s olivia includes features such as smart profile summary, AI-enabled notetaker, medical image sharing, health monitoring and direct data import.

iShares Russell Mid-Cap Value ETF

First Trust Exchange-Traded Fund VI - First Trust Nasdaq Artificial Intelligence and Robotics ETF

Tempus AI Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$170.07
Prev Close	$171.17
Open	$170.83
Dividend Yield	N/A
50-Day Moving Average	$166.71
Beta	N/A
Avg. Volume	331,566.46
PE Ratio	N/A

52-Week High	$173.52
52-Week Low	$133.74
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

IWS Fundamentals